Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 5
1985 8
1986 49
1987 25
1988 13
1989 15
1990 46
1991 16
1992 21
1993 22
1994 34
1995 29
1996 30
1997 30
1998 38
1999 50
2000 56
2001 59
2002 56
2003 61
2004 48
2005 48
2006 52
2007 61
2008 53
2009 70
2010 72
2011 59
2012 79
2013 80
2014 83
2015 97
2016 102
2017 85
2018 77
2019 87
2020 102
2021 129
2022 110
2023 104
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

2,104 results

Results by year

Filters applied: . Clear all
Page 1
Beta-blockers for the treatment of arrhythmias: Bisoprolol - a systematic review.
Muresan L, Cismaru G, Muresan C, Rosu R, Gusetu G, Puiu M, Mada RO, Martins RP. Muresan L, et al. Ann Pharm Fr. 2022 Sep;80(5):617-634. doi: 10.1016/j.pharma.2022.01.007. Epub 2022 Jan 31. Ann Pharm Fr. 2022. PMID: 35093388 Free article. Review.
The aim of this study was to analyze the current existing evidence for bisoprolol for the treatment of both supraventricular and ventricular arrhythmias. MATERIAL AND METHODS: Using the keywords "bisoprolol" and "arrhythmias" or "atrial fibrillation" or "ventricular …
The aim of this study was to analyze the current existing evidence for bisoprolol for the treatment of both supraventricular and vent …
Therapeutic Properties of Highly Selective beta-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.
AlHabeeb W, Mrabeti S, Abdelsalam AAI. AlHabeeb W, et al. Cardiovasc Drugs Ther. 2022 Oct;36(5):959-971. doi: 10.1007/s10557-021-07205-y. Epub 2021 Jun 9. Cardiovasc Drugs Ther. 2022. PMID: 34106365 Free PMC article. Review.
Bisoprolol and nebivolol are highly selective beta(1)-adrenoceptor antagonists, with clinical indications in many countries within the management of heart failure with reduced left ventricular ejection fraction (HFrEF), ischaemic heart disease (IHD), and hypertension. ...I …
Bisoprolol and nebivolol are highly selective beta(1)-adrenoceptor antagonists, with clinical indications in many countries within th …
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, Haynes S, Calvert MJ, Deeks JJ, Steeds RP, Strauss VY, Rahimi K, Camm AJ, Griffith M, Lip GYH, Townend JN, Kirchhof P; Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Kotecha D, et al. JAMA. 2020 Dec 22;324(24):2497-2508. doi: 10.1001/jama.2020.23138. JAMA. 2020. PMID: 33351042 Free PMC article. Clinical Trial.
INTERVENTIONS: Digoxin (n = 80; dose range, 62.5-250 mug/d; mean dose, 161 mug/d) or bisoprolol (n = 80; dose range, 1.25-15 mg/d; mean dose, 3.2 mg/d). ...Adverse events were less common with digoxin; 20 patients (25%) in the digoxin group had at least 1 AE vs 51 patients …
INTERVENTIONS: Digoxin (n = 80; dose range, 62.5-250 mug/d; mean dose, 161 mug/d) or bisoprolol (n = 80; dose range, 1.25-15 mg/d; me …
Bisoprolol: A comprehensive profile.
Bakheit AH, Ali R, Alshahrani AD, El-Azab AS. Bakheit AH, et al. Profiles Drug Subst Excip Relat Methodol. 2021;46:51-89. doi: 10.1016/bs.podrm.2020.07.006. Epub 2020 Sep 8. Profiles Drug Subst Excip Relat Methodol. 2021. PMID: 33461700
The present study describes a comprehensive profile of Bisoprolol including detailed nomenclature; formulae, elemental analysis, appearance, its uses, applications, and methods for the preparation are outlined. ...The mass fragmentation pattern of bisoprolol fuma …
The present study describes a comprehensive profile of Bisoprolol including detailed nomenclature; formulae, elemental analysis, appe …
Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
Yndigegn T, Lindahl B, Mars K, Alfredsson J, Benatar J, Brandin L, Erlinge D, Hallen O, Held C, Hjalmarsson P, Johansson P, Karlström P, Kellerth T, Marandi T, Ravn-Fischer A, Sundström J, Östlund O, Hofmann R, Jernberg T; REDUCE-AMI Investigators. Yndigegn T, et al. N Engl J Med. 2024 Apr 18;390(15):1372-1381. doi: 10.1056/NEJMoa2401479. Epub 2024 Apr 7. N Engl J Med. 2024. PMID: 38587241 Clinical Trial.
METHODS: In a parallel-group, open-label trial performed at 45 centers in Sweden, Estonia, and New Zealand, we randomly assigned patients with an acute myocardial infarction who had undergone coronary angiography and had a left ventricular ejection fraction of at least 50% to rec …
METHODS: In a parallel-group, open-label trial performed at 45 centers in Sweden, Estonia, and New Zealand, we randomly assigned patients wi …
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).
Cotton S, Devereux G, Abbas H, Briggs A, Campbell K, Chaudhuri R, Choudhury G, Dawson D, De Soyza A, Fielding S, Gompertz S, Haughney J, Lang CC, Lee AJ, MacLennan G, MacNee W, McCormack K, McMeekin N, Mills NL, Morice A, Norrie J, Petrie MC, Price D, Short P, Vestbo J, Walker P, Wedzicha J, Wilson A, Lipworth BJ. Cotton S, et al. Trials. 2022 Apr 14;23(1):307. doi: 10.1186/s13063-022-06226-8. Trials. 2022. PMID: 35422024 Free PMC article. Clinical Trial.
Observational studies consistently report that beta blocker use in people with COPD is associated with a reduced risk of COPD exacerbations. The bisoprolol in COPD study (BICS) investigates whether adding bisoprolol to routine COPD treatment has clinical and cost-ef …
Observational studies consistently report that beta blocker use in people with COPD is associated with a reduced risk of COPD exacerbations. …
First derivative synchronous spectrofluorimetric analysis of bisoprolol fumarate and ivabradine in pharmaceutical and biological matrices. Investigation of the method greenness.
Abo Elkheir SM, Zeid AM, Nasr JJM, Walash MI. Abo Elkheir SM, et al. Luminescence. 2022 Oct;37(10):1657-1665. doi: 10.1002/bio.4337. Epub 2022 Aug 8. Luminescence. 2022. PMID: 35834392
The estimation is based on measuring the first derivative of the synchronous fluorescence spectra of ivabradine and bisoprolol fumarate in ethanol at deltalambda = 80 nm. The peak amplitudes are measured at 234.4 nm (zero-crossing point of ivabradine) and 244.0 nm ( …
The estimation is based on measuring the first derivative of the synchronous fluorescence spectra of ivabradine and bisoprolol fum …
Bisoprolol in the treatment of chronic heart failure.
de Groote P, Ennezat PV, Mouquet F. de Groote P, et al. Vasc Health Risk Manag. 2007;3(4):431-9. Vasc Health Risk Manag. 2007. PMID: 17969374 Free PMC article. Review.
Bisoprolol fumarate is a highly selective beta-1 receptor blocker. Bisoprolol has been extensively studied in three large mortality trials in stable chronic heart failure (CHF) patients. ...There was no difference in morbidity and mortality between sub-groups …
Bisoprolol fumarate is a highly selective beta-1 receptor blocker. Bisoprolol has been extensively studied in three lar …
Bisoprolol-induced nightmares.
Kuriyama S. Kuriyama S. J Hum Hypertens. 1994 Sep;8(9):730. J Hum Hypertens. 1994. PMID: 7807505 No abstract available.
Pharmacogenetic polymorphisms affecting bisoprolol response.
Castaño-Amores C, Díaz-Villamarín X, Pérez-Gutiérrez AM, Antúnez-Rodríguez A, Pozo-Agundo A, Moreno-Escobar E, Sánchez-Ramos JG, Martínez-González LJ, Dávila-Fajardo CL. Castaño-Amores C, et al. Biomed Pharmacother. 2021 Oct;142:112069. doi: 10.1016/j.biopha.2021.112069. Epub 2021 Aug 27. Biomed Pharmacother. 2021. PMID: 34470728 Free article.
The ADRB1 Arg389Gly (rs1801253) was the most studied genetic polymorphism and it seems to influence the response to bisoprolol, although studies are inconclusive. Even, we performed a meta-analysis about its influence on systolic/diastolic blood pressure in patients treate …
The ADRB1 Arg389Gly (rs1801253) was the most studied genetic polymorphism and it seems to influence the response to bisoprolol, altho …
2,104 results